Avacta Receives Clinical Validation of AffiDX SARS-CoV-2 Antigen Lateral Flow Test

b'Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer\xc2\xae and pre|CISION\xe2\x84\xa2 platforms, is pleased to announce positive data from the clinical validation of its AffiDX\xc2\xae SARS-CoV-2 antigen lateral flow test.